Plus   Neg

AstraZeneca: Farxiga Meets Primary Endpoint In Phase III Trial - Quick Facts

AstraZeneca plc (AZN.L,AZN) reported positive results from the Phase III DAPA-HF trial, the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type-2 diabetes. In the trial, Farxiga showed efficacy and safety data for the treatment of patients with heart failure on top of standard of care. The safety profile was consistent with the established safety profile of the medicine.

AstraZeneca said it plans to discuss the results of the DAPA-HF trial with health authorities as soon as possible.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Textron Specialized Vehicles recalled 20,573 units of Gas-powered E-Z-GO, Cushman and Tracker brand off-road vehicles for possible fire hazard, a statement by the U.S. Consumer Product Safety Commission said. The company said starter generator wire can be improperly secured, allowing it to come into contact with the vehicle's exhaust that could cause a fire hazard. Delta Air Lines Inc. said Friday that it will invest $1 billion over the next decade to mitigate all greenhouse gas emissions from its global business, starting March 1, 2020. The company intends to become the first airline in the world to go carbon neutral. The airline said that over the next decade, it will spend $1 billion to drive innovation and advance clean-air travel technologies. Crown Castle International Corp. (REIT) (CCI) is currently gaining over 1% on Friday morning. Early this week, a U.S. District judge ruled in favor of Sprint and T-Mobile's long-pending $26 billion merger deal. The judge dismissed a lawsuit brought by a group of State Attorneys General. The deal is...
Follow RTT